雌三醇17-硫酸酯 | 42028-21-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 雌三醇17-硫酸酯
• 英文名称: estriol-17-sulfate
• 英文别名: Estriol 17-sulfate；[(8R,9S,13S,14S,16R,17R)-3,16-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] hydrogen sulfate
• CAS: 42028-21-7
• 化学式: C₁₈H₂₄O₆S
• 分子量: 368.451
• InChiKey: HTAOZBHEZQGPLH-ZXXIGWHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  Trikalium-oestriol-3,16,17-trisulfat 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 雌三醇17-硫酸酯
  参考文献：
  名称：

  Fex; Lundvall; Olsson, Acta Chemica Scandinavica (1947), 1968, vol. 22, # 1, p. 254 - 264

  摘要：

  DOI：

文献信息

• [EN] GPER PROTEOLYTIC TARGETING CHIMERAS<br/>[FR] CHIMÈRES DE CIBLAGE PROTÉOLYTIQUE GPER
  申请人：SALEM ALIASGER K

  公开号：WO2021217036A1

  公开（公告）日：2021-10-28

  A molecule comprising a G-protein coupled estrogen receptor (GPER) ligand coupled to a linker coupled to an E3 ubiquitin ligase ligand and methods of using the molecule are provided. In one embodiment, the GPER ligand is estradiol and the E3 ubiquitin ligase ligand is (S,R,S)- AHPC.

  提供了一种包含G蛋白偶联雌激素受体（GPER）配体、连接物和E3泛素连接酶配体的分子，以及使用该分子的方法。在一个实施例中，GPER配体是雌二醇，E3泛素连接酶配体是（S，R，S）-AHPC。
• Assay processes and materials therefor
  申请人：UNILEVER PLC

  公开号：EP0104926A2

  公开（公告）日：1984-04-04

  A process for carrying out a specific binding assay, for the qualitative detection or quantitative or semi-quantitative determination of an analyte which forms a component of a specific binding reaction, using a labelled conjugate form of a derivative or analogue of one of the relevant specific binding partners, said labelled form being capable of emitting delayed luminescence upon photo-excitation, characterised in that the labelled conjugate form of one of the relevant specific binding partners comprises a derivative or analogue of the specific binding partnerwith a derivative of a luminescent substance which shows a delayed light emission upon photoexcitation, the delayed light emission of which is subject to quenching by molecular oxygen, and characterised further in that the assay is carried out by the use of a time-resolved photometric method in the presence of an effective amount of a quench-inhibiting substance able to prevent quenching by molecular oxygen.

  一种进行特异性结合测定的工艺，用于定性检测或定量或半定量测定构成特异性结合反应成分的分析物，使用相关特异性结合伙伴之一的衍生物或类似物的标记共轭形式，所述标记形式在光激发时能够发出延迟发光、其特征在于，相关特异性结合剂之一的标记共轭形式包括该特异性结合剂的衍生物或类似物以及发光物质的衍生物，该发光物质在光激发时显示延迟发光，其延迟发光受分子氧淬灭的影响，其特征还在于，该检测是在存在有效量的淬灭抑制物质以防止分子氧淬灭的情况下，通过使用时间分辨光度法进行的。
• Total estriol fluorescence polarization immunoassay
  申请人：ABBOTT LABORATORIES

  公开号：EP0200960A1

  公开（公告）日：1986-11-12

  The present invention is directed to a homogeneous fluorescence polarization immunoassay for determining total estriol content in body fluids, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for preparing them. The assay is conducted by measuring the degree of polarization of plane polarized light that has been passed through a sample containing antiserum and tracer. The combination of antiserum and tracer used will possess excellent cross-reactivity to estriol-3-sulfate, eliminating the need for enzyme hydrolysis of this conjugate to free estriol.

  本发明涉及一种测定体液中总雌三醇含量的均相荧光偏振免疫测定法，涉及制备和进行这种测定所需的各种成分，以及制备这些成分的方法。 具体地说，本发明公开了示踪剂、免疫原和抗体，以及制备它们的方法。 该测定法是通过测量穿过含有抗血清和示踪剂的样品的平面偏振光的偏振程度来进行的。 所使用的抗血清和示踪剂的组合将对雌三醇-3-硫酸盐具有极好的交叉反应性，从而无需用酶水解这种共轭物来生成游离雌三醇。
• Pharmaceutical packaging for estriol therapy
  申请人：The Regents of the University of California

  公开号：US10369158B2

  公开（公告）日：2019-08-06

  This invention relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

  本发明涉及用于治疗神经退行性疾病（如多发性硬化症）的新型包装药品，以及使用这些产品的方法。
• Methods of monitoring estriol therapy
  申请人：The Regents of the University of California

  公开号：US10406169B2

  公开（公告）日：2019-09-10

  Provided are methods for treating a neurodegenerative disease, such as multiple sclerosis, in a subject receiving a first estriol treatment regimen, comprising obtaining a measurement of the serum estriol concentration in the blood of the subject, and administering a second estriol treatment regimen to the subject if the serum estriol concentration is less than 6 ng/mL. The daily amount of estriol administered during the second estriol treatment regimen is preferably greater than the daily amount of estriol administered during the first estriol treatment regimen.

  本发明提供了用于治疗接受第一种雌三醇治疗方案的受试者的神经退行性疾病（如多发性硬化症）的方法，包括测量受试者血液中的血清雌三醇浓度，如果血清雌三醇浓度低于6纳克/毫升，则对受试者施用第二种雌三醇治疗方案。在第二种雌三醇治疗方案中，每天施用的雌三醇量最好大于第一种雌三醇治疗方案中每天施用的雌三醇量。